| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 19 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 7.39M | $441.12M | - | |
| CEO | 890.4K | $53.16M | - | |
| CEO | 875.0K | $52.24M | - | |
| Other | 740.2K | $44.19M | - | |
| COO | 215.3K | $12.85M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 18, 2024 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 847 | $30.00 | $25,412.54 | - | -24.2% | -26.2% | |
| Oct 18, 2024 | Kintz Samuel50 | President And CEO | Sell | 924 | $30.00 | $27,722.68 | - | -24.2% | -26.2% | |
| Oct 18, 2024 | Collins Helen Louise64 | Chief Medical Officer | Sale+OE | 816 | $30.00 | $24,482.45 | -100% | -24.2% | -26.2% | |
| Oct 18, 2024 | Heyman Richard A.74 | Director | Sell | 1,570 | $30.00 | $47,104.03 | -1.0% | -24.2% | -26.2% | |
| Oct 15, 2024 | Heyman Richard A.74 | Director | Sell | 1,270 | $27.67 | $35,143.31 | -1.0% | -20.7% | -21.9% | |
| Oct 9, 2024 | Kintz Samuel50 | President And CEO | Sell | 29,977 | $28.07 | $841,334.38 | -0.7% | -15.4% | -24.5% | |
| Oct 9, 2024 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 51,145 | $28.11 | $1,437,585.19 | -1.2% | -15.4% | -24.5% | |
| Oct 8, 2024 | Ballal Rahul D.70 | Director | Sale+OE | 10,420 | $28.17 | $293,557.45 | -31.8% | -14.1% | -27.5% | |
| Oct 7, 2024 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 11,488 | $27.51 | $316,014.07 | -100% | -12.3% | -26.7% | |
| Oct 7, 2024 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 10,229 | $27.54 | $281,664.00 | -0.5% | -12.3% | -26.7% |